Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2025Journal of Education Health and SportOpen Access

Biomarkers of platinum resistance in serous ovarian cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

АРА. И. Рыбин

Discussion

Loading...

Member takes

Overview

This analysis identifies biomarkers linked to platinum resistance in patients with serous ovarian cancer, suggesting potential targets for treatment.

Key Points

  • The study finds higher ABCA1 expression in platinum-resistant ovarian cancer cases, indicating its role in resistance mechanisms.
  • A significant correlation exists between survivin levels, nitric oxide activity, and ABCA1 expression, pointing to potential biomarkers for resistance.
  • This research utilizes patient samples to explore relationships between various biomarkers and platinum drug efficacy.
  • Identifying these biomarkers may help tailor treatment strategies for patients with ovarian cancer, improving outcomes.

Cite This Study

А. И. Рыбин (2025) studied this question.

synapsesocial.com/papers/68d90a0641e1c178a14f62e1https://doi.org/10.12775/jehs.2025.85.65774
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunohistochemical parameters of serous ovarian carcinomas and possible mechanism of development of resistance to platinum-based drugs2024 · 1 citations
  2. 2Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models2024 · 1 citations
  3. 3RNA Sequencing Analysis for the Identification of Genes Associated with Cisplatin Resistance in Ovarian Cancer2024
  4. 4Abstract A025: Molecular signature of cisplatin resistance in ovarian cancer identifies therapeutic opportunities for re-sensitization2025
  5. 5Abstract 7683: A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer2026